Site is Being Upgraded

Taming cancers with anti-tapeworm drugs: Niclosamide (brand name: Niclocide, Fenasal, Phenasal), an anti-tapeworm drug,  increases the expression of tumor suppressors genes, such as CCM3/KRIT1, TPM1,  p53, TAp63, TAp73, INK4a/ARF, and others, and induces regression of p53-mutated human cancers and other cancers, via up-regulation of its target gene, 16/October/2018, 1.38 pm

Mechanistic insights into how anesthetic agent Sevoflurane may deteriorate memory, learning, and cognition: Sevoflurane (trade name: Sojourn, Ultane, Sevorane), a local anesthetic agent, decreases Tissue inhibitor of metalloproteinases 2 (TIMP2) and BDNF levels, attenuates cognition, and aggravates age-associated decline in memory and learning, via up-regulation of its target genes, 16/October/2018, 1.18 pm
October 16, 2018
Music as a pain medication: Music increases the expression of PD-L1, attenuates acute and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 17/Ocotober/2018, 7.04 pm
October 17, 2018
Show all

From Significance of the study to Public health relevance

Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53 pathway is altered in about 80% of tumors.; (3) our understanding is incomplete in terms of molecular targets and the oncogenic/malignant pathways involved in mutant p53-overexpressing tumors; (4) cancer causes the highest economic loss compared to all the known causes of death worldwide; and (5) cancer causes the considerable economic loss worldwide, there is an urgent need to find: (i) a cheaper alternative to the existing expensive drugs; (ii) a side-effect-free natural product-based drug; and (iii) a way to effectively treat and stall metastatic progression and relapse of mutant p53-overexpressing human cancers.


From therapeutic strategy to Research Findings:

(i) Therapeutic strategy: 

This study suggests a therapeutic strategy for stalling the progression of p53-deficient/deleted or mutant-p53 expressing metastatic cancers. By activating tumor suppressor p53’s unmutated “homologous protein such as TAp73/p63” in p53-deficient or mutant-p53 expressing metastatic cancer cells, one can stall their progression.

(ii) Research findings:  

This study suggests that Niclosamide may function as an anti-cancer agent in mutant p53 expressing human cancers. 

Figure 1. Mechanistic insight into how  Niclosamide (brand name: Niclocide, Fenasal, Phenasal) functions as an anticancer/antimetastatic agent in mutant p53-expressing tumors.  Tramadol (brand name: Ultram),  by activating tumor/metastasis suppressor genes, such as CCM3/KRIT1, TPM1, p53, TAp63, TAp73, INK4a, and ARF and others, in metastatic tumors, it may inhibit the progression of mutant-p53 expressing human cancers

Figure 2.  Niclosamide (brand name: Niclocide, Fenasal, Phenasal) functions as an anti-tumor/metastatic agent through induction of tumor/metastatic suppressor genes, such as  CCM3/KRIT1, TPM1, p53, TAp63, TAp73, INK4a, and ARF

 

 

 

 

 

 

 

 

 

 

This study suggests that Niclosamide, by increasing the expression of its target gene, it may increase the expression of tumor/metastasis suppressors genes, such as CCM3/KRIT1, TPM1, p53, TA-p73, TA-p63, INK4a, ARF, and others. Thereby, it may inhibit the migration and invasion of metastatic cancer cells expressing mutant-p53 (figure1).

 


Therapeutic opportunity:

Given the ability of Niclosamide to induce the expression of a number of tumor/metastasis suppressor genes, as indicated above, it may be used, either alone or in combination with other anticancer drugs, to inhibit the progression of not only p53-mutated invasive metastatic tumors, but also other aggressive human cancers. Taken together, this study suggests, for the first time, that oncologists may consider treating metastatic cancer patients with Niclosamide, as it may stall the progression of advanced metastatic cancers, by turning on the expression of  tumor/metastasis suppressors genes, such as CCM3/KRIT1, TPM1, p53, TA-p73, TA-p63, INK4a, ARF, and others(figure 2).


Details of the research findings

Idea Proposed/Formulated by Dr. L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $300#

Undisclosed mechanistic information: How Niclosamide increases the expression of tumor suppressor genes, such as  CCM3/KRIT1, TPM1, p53, TAp63, TAp73, and others,  in mutant p53 expressing cancer cells?

For purchase and payment details, you may reach us at admin@genomediscovery.org

#Research cooperation

[easy_payment currency=”USD”]

 


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Taming cancers with anti-tapeworm drugs: Niclosamide (brand name: Niclocide, Fenasal, Phenasal), an anti-tapeworm drug,  increases the expression of tumor suppressors genes, such as CCM3/KRIT1, TPM1,  p53, TAp63, TAp73, INK4a/ARF, and others, and induces regression of p53-mutated human cancers and other cancers, via up-regulation of its target gene, 16/October/2018, 1.38 pm, Genome-2-Biomedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.